Ian Frank, MD

Experts in HIV provide closing thoughts on the future of PrEP, including improvement of uptake and addressing access disparities.

Key opinion leaders in HIV describe factors to consider when evaluating which patients may benefit from long-acting injectable PrEP therapies.

A multidisciplinary panel of experts discuss pipeline medications for PrEP and effects of the USPSTF grading on emerging therapies.

Experts in HIV provide insight into the Grade A recommendation for HIV PrEP by the U.S. Preventive Services Task Force (USPSTF) and its impact on patients, clinicians, and payers.

Key opinion leaders in HIV discuss nonadherence to HIV PrEP and methods to address patient “walk away.”

Ian Frank, MD and Jeffrey Crowley, MPH provide insight into engaging clinicians for increased assessment of patients for PrEP.

Experts in HIV discuss methods to address the low rate of HIV PrEP uptake among at-risk individuals.

A multidisciplinary panel of experts discuss challenges to monitoring patient adherence and persistence to HIV PrEP.

Ian Frank, MD and Jeffrey Crowley, MPH address HIV PrEP adherence and persistence issues in the clinical practice setting.

Experts in HIV provide insight into payer coverage of HIV PrEP and patient barriers for receiving PrEP.

Carl Schmid, MBA and Ian Frank, MD discuss the process of initiating HIV PrEP beginning with a clinical patient evaluation.

Ian Frank, MD and Jeffrey Crowley, MPH describe the CDC PrEP Care System Process and eligibility criteria for receiving PrEP.

A multidisciplinary panel of experts provides an overview of the economic burden of HIV and the role of pre-exposure prophylaxis (PrEP) in preventing HIV transmission.